Bio-Techne invests in China-based cell and gene therapy media company

By The Science Advisory Board staff writers

January 28, 2021 -- Bio-Techne has made an initial minority strategic equity investment in Changzhou Eminence Biotechnology (Eminence). The companies will synergistically work on the development and commercialization of good manufacturing practice (GMP) molecules and proteins for cell and gene therapy media.

Eminence will use the funds to expand its manufacturing capacity and increase the service capabilities of its China-headquartered GMP media production facility. Eminence will leverage Bio-Techne's industry-wide recognition as a high-quality supplier to the life sciences industry and its existing relationships with biopharmaceutical companies.

Founded in 2016, Eminence is focused on supplying life science companies with media, including Chinese hamster ovary (CHO) cells and other serum-free media products, as well as custom cell line and media formulation development services. The company is in the process of completing and scaling its GMP production facility, which is expected to be finished by the end of 2021.

Copyright © 2021
To access all The ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
I have read and agree to the privacy policy and terms of service and wish to opt-in for

Already have an account? Sign in here